KRAS and pancreatic adenocarcinoma: In PAAD, KCNN4 expression was significantly elevated in tumors harboring KRAS mutations (p = 3.5e−16) and CDKN2A mutations (p = 2.1e−05), suggesting a possible link between KCNN4 and oncogenic signaling pathways.